Skip to main content

Table 2 Detailed treatment data according to first-line chemotherapy regimen

From: Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach

  Whole study population Matched population
FOLFIRINOX (n = 371) Gemcitabine/nab-paclitaxel (n = 157) P value FOLFIRINOX (n = 151) Gemcitabine/nab-paclitaxel (n = 151) P value
N of cycle during first-line chemotherapy 9 (4–15) 5 (3–8)   9 (4–15) 5 (3–8)
Treatment duration of first-line (months) 5.6 (1.8–9.8) 4.3 (2.3–7.0) 0.03 5.9 (2.2–10.1) 4.3 (2.2–6.9) 0.01
Dose reduction during first-line chemotherapy 172 (46.4) 57 (36.3)a 0.03 76 (50.3) 52 (34.4)a 0.01
Interruptionb chemotherapy due to AEs 25 (6.8) 46 (29.3) <  0.001 12 (7.9) 35 (23.1) <  0.001
 Cessation treatment 21 (5.7) 24 (15.3)   11 (7.3) 28 (18.5)  
 Change regimen 4 (1.1) 22 (14.0)   1 (0.7) 7 (4.6)  
Best responsec    0.33    0.29
 CR 4 (1.1) 0 (0) 0.18 3 (2.0) 0 (0)  
 PR 106 (28.9) 48 (32.4)   48 (32.0) 46 (32.4)  
 SD 166 (45.2) 71 (48.0)   64 (42.7) 68 (47.9)  
 PD 91 (24.8) 29 (19.6)   35 (23.3) 28 (19.7)  
Response ratesc
 ORR 110 (30.0) 48 (32.4) 0.58 51 (34.0) 46 (32.4) 0.77
 DCR 276 (75.2) 119 (80.4) 0.21 115 (76.7) 114 (80.3) 0.45
Second-line treatment 245 (69.2) 92 (58.6) 0.02 103 (71.5) 88 (58.3) 0.02
 FOLFIRINOX 61   59  
 Nab-paclitaxel 120   53  
 Clinical trial 33 5   14 4  
 Other Gemcitabined 86 0   34 0  
 Other 5-FUe 6 26   2 25  
  1. FFX FOLFIRINOX, GnP gemcitabine plus nab-paclitaxel, AEs adverse events, CR complete response, PR partial response, SD stable disease, PD progression of disease, ORR objective response rate, DCR disease control rate, 5-FU 5-fluorouracil, FOLFOX oxaliplatin plus 5-FU/leucovorin, FOLFIRI irinotecan plus 5-FU/leucovorin, iFAM infusional 5-FU plus doxorubicin and mitomycin-C
  2. aIncluded patients for whom nab-paclitaxel was omitted due to adverse events
  3. bDiscontinuation chemotherapy or switching of chemotherapy regimen
  4. cNot evaluated for patients with regimen change or death before response evaluation
  5. dIncluded gemcitabine single, gemcitabine plus erlotinib regimens
  6. eIncluded FL, FOLFOX, FOLFIRI, iFAM, capecitabine plus oxaliplatin, tegafur/gimestat/otastat potassium regimens